ProteoGenix and Cizzle Biotechnology Announce Successful Development of New Antibodies for Early Lung Cancer Detection Schiltigheim, France – In a groundbreaking collaboration, ProteoGenix, a leading antibody development contract research organization (CRO), has partnered with Cizzle Biotechnology Holdings PLC, an innovative UK-based diagnostics developer, to develop new antibodies targeting the…